WT1 and non-small cell lung carcinoma: In our work, the exposure of cancer cells to a combination of paclitaxel and TCPOBOP increased WT1 gene expression compared to that with treatment with paclitaxel or TCPOBOP alone, making combination treatment of CAR agonists with paclitaxel a potentially interesting option for NSCLC therapy.